The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts

Article ID	Journal	Published Year	Pages	File Type
10901926	Cancer Letters	2015	13 Pages	PDF

Keywords

MLC HRP FAK HUVEC SCID CA4 Bioluminescence imaging (BLI)Y-27632 combretastatin A-4 phosphate DAPI GI50 pMLC RhoA kinase FDA VDA PLSD Vascular disrupting agent (VDA)SDS PBS CA4P FITC DTT SRB 4′,6-diamidino-2-phenylindole DMSO Federal Drug Administration analysis of variance ANOVA bioluminescence imaging protected least significant difference BLI dithiothreitol Dimethyl sulfoxide myosin light chain sodium dodecyl sulfate Breast cancer Human umbilical vein endothelial cells sulforhodamine B Vascular disrupting agent Non-muscle myosin II Phosphate buffered saline fluorescein isothiocyanate Microtubules Horseradish peroxidase Propidium iodide focal adhesion kinase (FAK)combretastatin A-4 severe combined immunodeficiency focal adhesion kinase Rock

Related Topics

Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research

Preview

The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts

Authors

Tracy E. Strecker, Samuel O. Odutola, Ramona Lopez, Morgan S. Cooper, Justin K. Tidmore, Amanda K. Charlton-Sevcik, Li Li, Matthew T. MacDonough, Mallinath B. Hadimani, Anjan Ghatak, Li Liu, David J. Chaplin, Ralph P. Mason, Kevin G. Pinney,